Nucleic-acid QC bottleneck → automated capillary-electrophoresis & AI QC

Many academic core facilities, small clinical labs, and mid-size pharma groups face a persistent nucleic-acid QC bottleneck: manual gels and legacy capillary systems are low-throughput, operator-dependent, and consume disproportionate technician time as sample loads grow. Roughly 25,000 academic and commercial labs represent the addressable base, and sequencing-volume increases are forcing more QC per lab, creating real pain in throughput and reproducibility. A feasible product is a mid-range automated capillary-electrophoresis platform paired with on-instrument and cloud AI QC software that performs plate-based (96/384) runs, automated sample handling and LIMS integration, and outputs validated fragment calling, deconvolution and contaminant alerts. A commercial model combining a $100–200K instrument, consumables and service contracts (consistent with the $140K average lab spend over three years) plus SaaS for advanced analytics yields hardware plus recurring revenue. This is a timely opportunity: the estimated market is about $3.5B (25,000 labs × $140K/3 years), sequencing throughput is increasing, AI signal-processing has matured, and decentralized genomics expands demand for mid-range instruments—factors reflected in a market score of 90/100 and revenue potential of 88/100. Those trends lower technical risk and increase the potential buyer pool, but they also invite competition from incumbents and niche CE providers. To stand out you need demonstrable gains in accuracy and time-to-result from ML-driven signal processing, turnkey LIMS/clinical workflow validation, and a clear total cost of ownership advantage via consumables and service economics. Be realistic about the hurdles: hardware development costs, multi-site clinical validation, multi-quarter sales cycles, and incumbent relationships mean success will require strong validation data, pilot partnerships, and disciplined execution rather than just a clever algorithm.